Polycystic ovary syndrome (PCOS) is a complex endocrine and metabolic disorder, typically
characterized by anovulation, infertility, obesity, insulin resistance, and polycystic ovaries …

Polycystic ovary syndrome (PCOS) was hypothesized to result from functional ovarian
hyperandrogenism (FOH) due to dysregulation of androgen secretion in 1989–1995 …

Several inositol isomers and in particular myo-inositol (MI) and D-chiro-inositol (DCI), were
shown to possess insulin-mimetic properties and to be efficient in lowering post-prandial …

(1) Background: Myoinositol (MI) and D-chiro-inositol (DCI) are involved in a number of
biochemical pathways within oocytes having a role in oocyte maturation, fertilization …

Polycystic ovary syndrome (PCOS) is a heterogenous disorder characterized by chronic
ovulation dysfunction and hyperandrogenism. It is considered the most common …

Background A couple may be considered to have fertility problems if they have been trying
to conceive for over a year with no success. This may affect up to a quarter of all couples …

Myo-inositol (MI) and D-chiro-inositol (DCI) are insulin second messengers, and MI is
involved in follicular gonadotropin pathways which orchestrate ovulation. The tissue-specific …

Polycystic ovary syndrome (PCOS) is a common endocrine disorder, with complex etiology
and pathophysiology, which remains poorly understood. It affects about 5–10% of women of …

Inositols are insulin-sensitizing compounds of promising efficacy in the management of
polycystic ovary syndrome (PCOS). On the one hand, myo-inositol (myo-ins) plays a …

Polycystic ovary syndrome (PCOS) is marked in 30 to 40% by insulin resistance and
hyperandrogenism. Myo-inositol (MI) increases insulin sensitivity, decreases …